These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31239736)

  • 1. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
    Schlueter M; Finn E; Díaz S; Dilla T; Inciarte-Mundo J; Fakhouri W
    Clinicoecon Outcomes Res; 2019; 11():395-403. PubMed ID: 31239736
    [No Abstract]   [Full Text] [Related]  

  • 2. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
    Wehler E; Boytsov N; Nicolay C; Herrera-Restrepo O; Kowal S
    Pharmacoeconomics; 2020 Jan; 38(1):39-56. PubMed ID: 31452079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
    Claxton L; Jenks M; Taylor M; Wallenstein G; Mendelsohn AM; Bourret JA; Singh A; Moynagh D; Gerber RA
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1088-102. PubMed ID: 27579831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China.
    Li S; Li J; Peng L; Li Y; Wan X
    Rheumatol Ther; 2021 Jun; 8(2):863-876. PubMed ID: 33893943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
    Chen DY; Hsu PN; Tang CH; Claxton L; Valluri S; Gerber RA
    J Med Econ; 2019 Aug; 22(8):777-787. PubMed ID: 30982378
    [No Abstract]   [Full Text] [Related]  

  • 12. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
    Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
    Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Value of Sarilumab Monotherapy for Adults with Moderately to Severely Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Chapman RH; Kumar VM; Synnott PG; Agboola F; Campbell JD
    J Manag Care Spec Pharm; 2019 Jan; 25(1):80-87. PubMed ID: 30589626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
    Emery P; Durez P; Hueber AJ; de la Torre I; Larsson E; Holzkämper T; Tanaka Y
    Arthritis Res Ther; 2021 Jan; 23(1):3. PubMed ID: 33397481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
    Van De Laar CJ; Oude Voshaar MAH; Fakhouri WKH; Zaremba-Pechmann L; De Leonardis F; De La Torre I; Van De Laar MAFJ
    Clinicoecon Outcomes Res; 2020; 12():213-222. PubMed ID: 32346301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
    Kremer JM; Schiff M; Muram D; Zhong J; Alam J; Genovese MC
    RMD Open; 2018; 4(1):e000581. PubMed ID: 29479473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
    Lopez-Romero P; de la Torre I; Haladyj E; Aletaha D; Smolen JS
    Ann Rheum Dis; 2022 May; 81(5):622-631. PubMed ID: 35193872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
    Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
    J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND.
    van der Heijde D; Kartman CE; Xie L; Beattie S; Schlichting D; Mo D; Durez P; Tanaka Y; Fleischmann R
    J Rheumatol; 2022 Feb; 49(2):133-141. PubMed ID: 34526397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.